Workflow
可靠股份(301009) - 2025 Q1 - 季度财报
301009Coco Healthcare(301009)2025-04-27 08:25

Financial Performance - The company's revenue for Q1 2025 was CNY 280,180,366.57, a decrease of 0.98% compared to CNY 282,967,455.35 in the same period last year[6] - Net profit attributable to shareholders was CNY 18,589,628.07, reflecting a 1.41% increase from CNY 18,331,987.65 year-on-year[6] - Basic earnings per share increased by 3.56% to CNY 0.0698, up from CNY 0.0674 in the same period last year[6] - Operating profit increased to ¥21,892,829.70, compared to ¥20,801,784.53 in the previous period, marking a growth of 5.24%[24] - Net profit for the current period is ¥18,614,887.13, slightly up from ¥18,204,327.14, representing an increase of 2.25%[25] Cash Flow - The net cash flow from operating activities surged by 112.42% to CNY 29,167,275.17, compared to CNY 13,731,198.53 in the previous year[12] - Cash received from sales and services was ¥267,053,603.28, down from ¥269,780,463.66, a decrease of 1.01%[27] - Net cash flow from operating activities was $29,167,275.17, an increase from $13,731,198.53 in the previous period, reflecting a positive trend in operational efficiency[28] - Total cash inflow from investment activities amounted to $112,033,319.66, significantly higher than $4,600,000.00 in the prior period, indicating strong investment recovery[28] - Cash outflow from investment activities was $8,585,517.35, down from $28,529,423.70, leading to a net cash flow from investment activities of $103,447,802.31, a substantial improvement[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,093,650,724.41, a slight increase of 0.20% from CNY 2,089,561,649.59 at the end of the previous year[6] - Total current assets increased to ¥1,292,528,954.09 from ¥1,275,660,793.30[19] - Total non-current assets decreased to ¥801,121,770.32 from ¥813,900,856.29[19] - Total liabilities increased, with short-term borrowings at ¥100,329,163.01[20] - Total liabilities decreased to ¥663,532,058.13 from ¥678,058,135.61, a reduction of 2.16%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,358[15] - Major shareholder Jin Liwei holds 30.13% of shares, totaling 81,909,282 shares[15] - Major shareholder Bao Jia holds 29.13% of shares, totaling 79,190,682 shares[15] Research and Development - Research and development expenses rose by 15.34% to CNY 11,782,913.68, indicating a focus on innovation[12] - Research and development expenses rose to ¥11,782,913.68 from ¥10,215,780.02, an increase of 15.37%[24] Investment Income - The company reported a significant increase in investment income, reaching CNY 2,122,287.33, compared to a loss of CNY 885,966.04 in the previous year[12]